Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma (Protocol-A)
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring intraocular lymphoma, primary central nervous system lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed intermediate- or high-grade primary CNS lymphoma documented by brain biopsy or cerebrospinal fluid or vitrectomy analysis Diagnosed within the past 90 days No systemic lymphoma NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age 16 to 75 Performance status ECOG 0-3 OR Karnofsky 40-100% Life expectancy Not specified Hematopoietic WBC at least 2,500/mm^3 Hematocrit at least 25% (transfusion allowed) Absolute granulocyte count at least 1,200/mm^3 Platelet count at least 100,000/mm^3 OR at least lower limit of normal (transfusion independent) Hepatic Bilirubin no greater than 2.0 times upper limit of normal Renal Creatinine clearance at least 30 mL/min Cardiovascular Adequate cardiac function to tolerate general anesthesia Pulmonary Adequate pulmonary function to tolerate general anesthesia Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for 2 months before and during study participation No other uncontrolled, clinically significant confounding medical condition within the past 30 days No known allergy to study agents HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) Single-agent methotrexate administered within the past 14 days allowed Endocrine therapy Not specified Radiotherapy No prior cranial or spinal radiotherapy Surgery Prior surgery or biopsy allowed
Sites / Locations
- Oregon Health & Science University Cancer Institute